Genmab — November 2019
-
695 Efficacy and Tolerability of (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study https://ash.confex.com/ash/2019/webprogram/Paper121694.html
-
from
Luciano J Costa
@End_myeloma
https://ash.confex.com/ash/2019/webprogram/Paper123401.html
This is big news. I honestly can't think of any other intervention in MM with this much impact in survival. Congratulations to the Alcyone team
@mvmateos
#ASH2019 #mmsm
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind